Resolian and GoBroad Healthcare Group Partnership Streamlines China-Global Clinical Trial Access

january 20, 2026

Resolian – a global contract research organization (CRO) specializing in bioanalysis and analytical sciences – officially signed a nonexclusive strategic partnership agreement with GoBroad Healthcare Group, a China-based, clinically focused innovation technology platform and Academic Research Organization (ARO).

This partnership represents a significant milestone in both organizations’ efforts to expand their service capabilities and strengthen regional collaborations. Resolian becomes the preferred partner for GoBroad providing bioanalytical and biomarker analyses for clinical trials.

By integrating GoBroad’s clinical expertise and operational execution strengths with Resolian’s global laboratory network and advanced analytical capabilities, the partnership is expected to better support clients in advancing global research and development programs with greater speed, consistency, and confidence.

This nonexclusive strategic partnership streamlines the ability for pharmaceutical companies outside of China to access GoBroad’s vast clinical trial resources in China through Resolian and for Chinese pharmaceutical companies working with GoBroad to leverage Resolian globally for their bioanalytical and biomarker work the next phases of drug development outside of China.

Resolian and GoBroad Healthcare Group Partnership Streamlines China-Global Clinical Trial Access
Resolian and GoBroad Healthcare Group Partnership Streamlines China-Global Clinical Trial Access
Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.